Clinical outcome
PD, SD, ASPS, Tumor
DISEASE, ALVEOLAR SOFT PART SARCOMA, OSTEOSARCOMA, TUMOR
The median follow-up duration for PFS was 8.34 months (Q1, Q3, 5.78, 8.34) (Fig. Kaplan–Meier curves for PFS. ASPS, alveolar soft part sarcoma. PFS, progression free survivalNo patient achieved CR. Notably, 2 patients with ASPS achieved PR; the ORR and DCR of ASPS were 33.3% (2/6) and 66.7% (4/6), respectively. Tumor response was observed in two patients, and the ORR was 18.2% (2/11) for the overall population. In addition, 3 patients had stable disease (SD) (2 with ASPS and 1 with osteosarcoma), and the DCR was 45.5% (5/11) for the entire population (Figs. Waterfall plot for best percentage change in target lesion size in FAS. ASPS, alveolar soft part sarcoma. PD, progressive disease; SD, stable disease; PR, partial response; FAS, full analysis setSpider plot for best percentage change in target lesion size in FAS. ASPS, alveolar soft part sarcoma. PD, progressive disease; SD, stable disease; PR, partial response; FAS, full analysis set